



Pioneering science delivers
vital medicines™

AMGEN BC QUICK FACTS

Amgen applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen believes in the transformative power of science to bring the benefits of biotechnology to more people than ever before. Amgen's Canadian research facility in Burnaby, British Columbia plays an important role in contributing to our more than 35-year legacy as a global leader in the identification, isolation, production and use of human proteins as therapeutic agents. The Amgen commercial team in BC works in partnership with the provincial government and other stakeholders to bring practical, cost-effective and long-term improvements to the healthcare system in British Columbia.

Today, Amgen scientists in Burnaby work on the cutting edge between the traditional disciplines of chemistry, cellular and molecular biology in an effort to discover and develop pioneering medical treatments. Our research leverages new scientific breakthroughs for patient care – from the laboratory to treatment – faster and safer than ever before, helping patients in their fight against cancer, bone disease, kidney disease, rheumatoid arthritis, cardiovascular disease and other serious illnesses.

AMGEN BC'S INNOVATIVE RESEARCH TECHNOLOGIES

Amgen BC's research centre is a custom-built, state-of-the-art laboratory, incorporating novel, proprietary technologies to isolate, develop and produce potential medicines. This world-class biotechnology lab enables Amgen BC to produce superior research results that translate into better therapeutic treatments.

Key to Amgen BC's leadership in biotechnology is our focus on advancing Amgen's most promising, innovative, potential new therapeutics into clinical studies, while significantly expanding the organization's understanding of the underlying causes of diseases.

The Amgen BC site is a research leader, as it operates the Xenomouse® process responsible for generating all of the company's internal discovery phase therapeutic human antibody candidates. Other advanced technologies which accelerate Amgen's ability to identify the best potential research candidates and isolate individual cells for further study have been developed at the Amgen BC site. These progressive research technologies can leverage new scientific breakthroughs for patient care faster and safer than ever before.

As a result of these technologies, four biologic medicines have been produced and developed into five products that are available to patients around the world:

Vectibix® (panitumumab), Xgeva® (denosumab), Prolia® (denosumab), Repatha® (evolocumab), and Aimovig™ (erenumab).

QUICK FACTS

Location

Burnaby, British Columbia

Staff

Burnaby Research & Development – 62
Field Staff – 14

Address/Phone

Amgen British Columbia
7990 Enterprise Street
Burnaby, British Columbia
Canada V5A 1V7
(604) 415-1800

HISTORY IN CANADA

1991 – Amgen Canada founded in Mississauga

1992 – Launch of NEUPOGEN®

1999 – Launch of STEMGEN®

2002 – Launches of Aranesp® and Kineret®,
Amgen acquires Immunex, including
Enbrel®

2004 – Launch of Neulasta® and Sensipar®

2005 – Kepivance® approved for use in
Canada

2006 – Amgen acquires Abgenix, Inc.,
including its Burnaby R&D group

2008 – Launch of Vectibix®

2009 – Launch of Nplate®

2010 – Launch of Prolia®

2011 – Launch of XGEVA®

2015 – Launch of Repatha®

2016 – Launch of Blnicyto®

2016 – Launch of Kyprolis®

AMGEN MEDICINES AVAILABLE IN BC

Oncology

Aranesp® (darbepoetin alfa)
Neulasta® (pegfilgrastim)
NEUPOGEN® (filgrastim)
Vectibix® (panitumumab)
XGEVA® (denosumab)
Blincyto® (blinatumomab)
Kyprolis® (carfilzomib)

Nephrology

Aranesp® (darbepoetin alfa)
Sensipar® (cinacalcet)

Rheumatology

Enbrel® (etanercept)

Dermatology

Enbrel® (etanercept)

Bone Health

Prolia® (denosumab)

Hematology

Nplate® (romiplostim)

Cardiology

Repatha® (evolocumab)

ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.ca and follow us on [www.twitter.com/amgen](https://twitter.com/amgen).

COMMITMENT TO BRITISH COLUMBIA

Amgen believes that biologic medicines have the power to change the ways we can fight disease and promote health, and the exciting scientific research being conducted in British Columbia is leading the way. Amgen's leadership in biotherapeutic research is underscored by our corporate commitment to re-investing our sales revenue back into research in Canada. Our Burnaby facility represents a robust and ongoing investment in the BC life sciences industry.

Many of Amgen BC's proprietary research innovations were developed or invented in BC – a testament to the tremendous scientific talent pool that has been trained here and works in this province. We strive to attract the best and brightest minds from British Columbia's post-secondary and graduate science education programs. We also believe in investing in tomorrow's great scientists, providing nurturing opportunities for aspiring students to gain solid work experience through active participation in BC's co-operative education programs and other science education and mentoring programs. Participating BC universities include the University of British Columbia, Simon Fraser University, BC Institute of Technology and the University of Victoria.

COMMUNITY INVOLVEMENT

As a leading member of the biotechnology sector, Amgen is committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by helping educators to teach more effectively; and improving access to science resources for teachers, students and the community at large.

Since 2010, Amgen has supported the national non-profit group Let's Talk Science in the development and release of a series of research reports that highlight the importance of science learning for students, parents, teachers and the economy. These research reports can be accessed by visiting: <http://www.letstalkscience.ca/research-publications/spotlight-on-science-learning.html>.

As a science-based company, Amgen also understands the benefits of science education, how critical STEM is to jobs and how science can power Canada's future prosperity and success for our youth. This is why Amgen is also proud to support Let's Talk Science's latest initiative, Canada 2067, an initiative to unite Canadians around a new vision for youth STEM learning with a focus on Kindergarten to Grade 12. Visit www.canada2067.ca for more information.

Further, Amgen dedicates substantial resources to strengthen and enrich communities in BC and across Canada by supporting the Advanced Coronary Treatment (ACT) Foundation of Canada as a national partner. The ACT Foundation is dedicated to establishing free, life-saving CPR and defibrillator training as a mandatory program in every Canadian high school.

